Targeted News Service

Johnson & Johnson announces new data showing TREMFYA(r) (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
October 19, 2026

NEW BRUNSWICK, New Jersey, Oct. 19 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson announces new data showing TREMFYA(r) (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

*

Spring House, Pa (October, 19, 2026) - Johnson & Johnson today announced one-year results from the Phase 3 FUZION stu . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form